MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation

✍ Scribed by Liming Wu; Xiaobo Xu; Juwei Shen; Haiyang Xie; Songfeng Yu; Tingbo Liang; Weilin Wang; Yan Shen; Min Zhang; Shusen Zheng

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 109 KB
• Volume: 96
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.20774

✦ Synopsis

Abstract

Background and Objectives

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major cause of post‐LT death. However, currently there is still lacking the markers to reliably predict recurrence. This study was undertaken to evaluate the association between three polymorphisms (C1236T, G2677A/T, C3435T) of Multidrug resistance 1 (MDR1) gene and the risk of recurrence after LT.

Methods

Genomic DNA of 99 HCC patients undergoing LT was extracted from peripheral blood lymphocytes and genotyping was performed using polymerase chain reaction‐restriction fragment length polymorphism assay. Cox proportional hazard model was used to estimate the hazard ratios associated with polymorphisms.

Results

During a mean follow‐up of 14.9 months, 49 patients experienced recurrence. The association between recurrence‐free and 2677A carrier (carrying at least one variant A allele) was significant (P = 0.019). However, no significant association was observed in other polymorphisms. Patients with 2677A carrier conferred a 63% reduction in recurrence risk compared with 2677A non‐carrier (odds ratio: 0.374; 95% confidence interval: 0.177–0.788; P = 0.010). The median recurrence‐free survival for 2677A carrier group was significantly longer than that for 2677A non‐carrier group (44.2 vs. 10.5 months, P = 0.015).

Conclusion

The polymorphism of MDR1 gene may be a valuable molecular marker for HCC recurrence after LT. J. Surg. Oncol. 2007;96:62–68. © 2007 Wiley‐Liss, Inc.